HIGHFDA DEVICE

Tandem Diabetes Care Insulin Infusion Pumps Recalled 1,380 Units in 2026 Over Czech Guide Error

Tandem Diabetes Care recalled 1,380 insulin infusion pumps distributed internationally in the Czech Republic and Slovakia after translation errors in the Czech user guide could cause unintended insulin delivery. The most significant error told users to verify the infusion set is connected to the body when it should be confirming it is not connected. Following this instruction could result in a hyp

Official notice
Tandem Diabetes CareHealth & Personal CareMedical DevicesVersion 7.8.1/ UDI: (01)008500066132625

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DEVICE
Recall date
January 30, 2026
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
January 30, 2026
Hazard Level
HIGH
Brand
Tandem Diabetes Care
Category
Health & Personal Care
Sold At
Multiple Retailers
At-Risk Groups
GENERAL, PREGNANT, CHILDREN

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Medical Devices; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
Tandem Diabetes Care
Product type
Insulin Infusion Pump
Model numbers
Version 7.8.1/ UDI: (01)008500066132625
Sold at
Multiple Retailers

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    January 30, 2026

  2. Reported by FDA DEVICE

    April 1, 2026

  3. RecallRadar source check

    April 8, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

The Czech language user guide contained multiple translation errors. The most significant error was that it incorrectly instructs users to verify that the infusion set is connected to the body, when it should instead direct users to confirm that the infusion set is not connected to the body. Following this instruction could result in unintended insulin delivery, potentially leading to a hypoglycemic event.

What You Should Do

Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Tandem Diabetes Care, Inc. or your healthcare provider for instructions. Notification method: Letter

About This Product

Tandem insulin infusion pumps deliver basal and bolus doses of insulin via a disposable cartridge. The device uses a motor-driven mechanism and is programmable by the user to manage insulin delivery.

Why This Is Dangerous

A translation error in the Czech user guide could cause unintended insulin delivery by instructing users to verify the infusion set is connected to the body, when it should be confirmed as not connected. This could lead to hypoglycemia.

Industry Context

This recall is not indicated as part of a broader industry pattern.

Real-World Impact

The recall highlights the risk of user-facing documentation causing incorrect device operation. Consumers should stop using affected pumps and await manufacturer guidance to avoid hypoglycemia.

Practical Guidance

How to identify if yours is affected

  1. Check model version and UDI on device label.
  2. Review the Czech user guide for translation accuracy related to infusion-set connection.

Where to find product info

On device label, packaging, recall letter, or the manufacturer’s website

What timeline to expect

Timelines vary; expect 4-8 weeks for remedy processing in typical cases

If the manufacturer is unresponsive

  • Document all communications with the manufacturer
  • Escalate to the regulator if the company is unresponsive
  • Consult healthcare providers for interim insulin management

How to prevent similar issues

  • Verify manuals before use and ensure the language matches your reading comprehension
  • Request updated instructions if you operate in a non-native language region
  • Keep a copy of recall communications and model numbers

Documentation advice

Keep the recall notification, purchase receipts, model numbers, and all correspondence with the manufacturer

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Model: Version 7.8.1 / UDI: (01)008500066132625 Sold internationally in the Czech Republic and Slovakia Recall date: 2026-01-30 Reported date: 2026-04-01 Price: Unknown Quantity: 1,380 units

Reported Incidents

No injuries or incidents have been reported.

Key Facts

  • Countries affected: Czech Republic, Slovakia
  • Hazard: unintended insulin delivery and potential hypoglycemia
  • No injuries reported
  • Recall status: ACTIVE

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERALPREGNANTCHILDRENPETS
Injury Types
OTHER

Product Details

Model Numbers
Version 7.8.1/ UDI: (01)008500066132625
Report Date
April 1, 2026
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
MEDIUM

Taro Pharmaceuticals Withdraws Diclofenac Sodium Gel Over Viscosity Issues

Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.

BEEKEEPER'S NATURALS USA
Microbial Contamination
Read more
Health & Personal Care
MEDIUM

AvKARE Recalls Rosuvastatin Tablets Due to Dissolution Issues

AvKARE recalled 7,991 cartons of Rosuvastatin Tablets on December 31, 2025. The recall stems from the product being out of specification for dissolution. Consumers should stop using the medication immediately and consult healthcare providers for guidance.

SUN PHARMACEUTICAL INDUSTRIES
Labeling: Not
Read more